Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atezolizumab + ipilimumab
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Atezolizumab + ipilimumab is an investigational drug combination of two immune checkpoint inhibitor monoclonal antibodies: atezolizumab, an anti–PD-L1 antibody, and ipilimumab, an anti–CTLA-4 antibody. Both agents work by potentiating T-cell mediated immune responses against cancer cells, but via different immune checkpoints—inhibiting PD-L1 and CTLA-4 respectively. This combination is being explored to enhance antitumor immune activity beyond what is achieved with either agent alone. Trials have focused on advanced solid tumors, including renal cell carcinoma and melanoma[4][1].
- Other names
- atezolizumab + ipilimumab
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on atezolizumab + ipilimumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atezolizumab + ipilimumab.